Company / Interest Expense
RECURSION PHARMACEUTICALS, INC. Interest Expense History
FY2019-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$97.0K
FY2023
5-year range
$97.0K / $3.0M
FY2019-FY2023
Trend
-92.9%
vs FY2022
Sector context
#38 of 44
Health Care
What the data says
RECURSION PHARMACEUTICALS, INC.'s interest expense of $97,000 is lower than 86% of companies in the Health Care sector (FY2023). Improved from $3M to $97,000 over the past 2 years.
Based on SEC 10-K filings.
$97,000 in FY2023 with a 3-year CAGR of -58.5%.
Improved from $3M to $97,000 over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -58.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 44This company $97.0K Sector average $291.0M
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -58.5%, indicating a declining trend.
- In FY2023, interest expense decreased 92.9% year-over-year.
- Ranks #38 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $97.0K | -92.9% |
| FY2022 | $1.4M | -53.9% |
| FY2021 | $3.0M | +117.1% |
| FY2020 | $1.4M | +114.2% |
| FY2019 | $635.0K | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026